Hypothesis

Coordinated delivery of a germline‑derived "cheating" toolkit—telomerase (TERT), the recombination factor ZSCAN4, and a selective autophagy regulator (e.g., ATG5)—to post‑mitotic somatic tissues using liver‑detargeted, myotropic AAV capsids will recapitulate the germline’s selection‑pressure–driven maintenance of replicative capacity. By simultaneously activating telomere lengthening, recombination‑based telomere repair, epigenetic reset, and damage clearance, somatic cells will experience a germline‑grade editing budget that extends healthspan without increasing tumorigenesis.

Mechanistic Rationale

• Telomerase alone is insufficient: TRF1 overexpression only benefits very old mice, indicating that telomere maintenance requires complementary pathways [PMC6563133]
• Germline uses multiple mechanisms: ZSCAN4‑mediated telomere recombination, enhanced DNA repair, epigenetic reprogramming, and selective autophagy act together to prevent mutation accumulation [PMC6563133]
• AAV engineering enables precise delivery: Machine‑guided capsid evolution yields >1000‑fold tissue specificity, allowing muscle‑focused expression while detargeting liver [Wyss][GlobalGenes]
• Multi‑gene payloads are feasible: Synthetic capsids such as AAV‑DJ efficiently package multi‑gene cassettes, making combinatorial delivery technically achievable [DOI:10.1038/s41467-018-05059-x]
• Transient, inducible expression mitigates oncogenic risk: Controlled TERT activation reverses degeneration without cancer [PMC6563133]; pairing with inducible promoters (e.g., doxycycline‑responsive) permits temporal gating of the entire toolkit.

Testable Predictions

1. Healthspan extension: Mice receiving AAV‑mediated co‑delivery of TERT, ZSCAN4, and ATG5 to skeletal muscle will show ≥15 % increase in median lifespan and improved grip strength, glucose tolerance, and frailty indices relative to AAV‑TERT alone.
2. Telomere dynamics: Muscle telomere length will be stabilized or lengthened, with a reduction in telomere‑associated DNA damage foci (TAFs) and an increase in ZSCAN4‑dependent recombination circles (T‑circles).
3. Epigenetic and autophagic markers: Global H3K9me3 loss (indicating a more open chromatin state) and elevated LC3‑II/I ratio will be observed, mirroring germline epigenetic plasticity.
4. Safety: No rise in tumor incidence or hyperplasia will be detected in treated cohorts over a 2‑year observation period, comparable to AAV‑TERT controls.
5. Dependency on coordination: Animals receiving any single factor (TERT, ZSCAN4, or ATG5) alone will not reproduce the full healthspan benefit, confirming the necessity of simultaneous germline‑like pathway activation.

Falsifiability

If co‑delivery fails to improve any healthspan metric, or if tumor rates rise significantly above controls, the hypothesis that germline‑grade multi‑factor activation confers somatic longevity without oncogenic cost would be refuted. Likewise, absence of telomere stabilization or epigenetic/autophagic changes despite transgene expression would indicate that the proposed mechanistic synergy does not occur in somatic cells.